Angiotensin Converting Enzyme 2 News and Research

RSS

Development of a model of substrate coordination to Zn-bound ACE2

The ongoing coronavirus disease-19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has claimed more than 2.8 million lives worldwide. Authorities are facing difficulty in preventing the spread of disease due to the highly infectious nature of SARS-CoV-2. Therefore, reducing the virus's ability to infect an individual's respiratory epithelial cells could prove an effective measure to prevent disease transmission.

31 Mar 2021

Researchers develop novel test that screens for SARS-CoV-2 variants of concern

A team of scientists from the United States has recently developed a single-tube duplex molecular assay for rapid detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants containing E484K and N501Y spike mutations.

30 Mar 2021

Researchers develop broadly neutralizing SARS-CoV-2 ferritin nanoparticle vaccine

In the continued need for next-generation vaccines that confer broad protection against COVID-19, scientists developed an adjuvanted SARS-CoV-2 Spike Ferritin Nanoparticle (SpFN) vaccine.

30 Mar 2021

Using ACE2 structure to predict SARS-CoV-2 susceptibility in animals

Researchers based at the Rice University, Texas, USA, have now demonstrated a novel method of predicting a species' susceptibility to contracting COVID-19, based on the animal's structure of ACE2.

30 Mar 2021

Study identifies key features in SARS-CoV-2 genome essential for replication in respiratory cells

Researchers at the Institute of Medical Virology, the University of Zurich in Switzerland, have identified features in the SARS-CoV-2 genome that are important for human respiratory cell growth.

29 Mar 2021

Addressing the increasing plasticity of SARS-CoV-2

Researchers summarize what this rapid increase of plasticity of SARS-CoV-2 could mean for the future of the pandemic and anti-SARS-CoV-2 measures.

29 Mar 2021

Developing orally administrable drugs to combat SARS-CoV-2

Researchers in China have reported the successful design and synthesis of two antiviral compounds that target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)’s main protease, essential in virus replication.

29 Mar 2021

Virus-cell interaction may partly explain the higher infection rate of COVID-19

Bioengineering researchers at Lehigh University have identified a previously unknown interaction between receptors in human cells and the spike, or "S," protein of SARS-CoV-2, the virus that causes COVID-19.

29 Mar 2021

Antibody agents effective at neutralizing European, South African, and United States SARS-CoV-2 variants

Researchers in the United States have demonstrated the effectiveness of three antibody agents at neutralizing recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic.

28 Mar 2021

New SARS-CoV-2 genome variants identified in US mink

Researchers in Canada have discovered two novel variants in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) gene sequences collected from mink in the United States.

28 Mar 2021

Identification of specific anti-SARS-CoV-2 antibodies with cross-neutralization potency

A team of scientists from the USA and Canada recently characterized the cross-neutralizing potency of anti-SARS-CoV-2 antibodies isolated from COVID-19 patients. The findings reveal that some of the isolated antibodies targeting the spike RBD and the S2 subunit are capable of cross-neutralizing other members of the human beta-coronavirus family.

25 Mar 2021

Fluoxetine (Prozac) performs strongly in vitro against SARS-CoV-2 (including mutants)

Researchers from Finland, to expand on these studies, tested some of these drugs against the new SARS-CoV-2 variants. The study is published on the preprint server bioRxiv.

24 Mar 2021

Pangolin coronavirus sheds light on UK SARS-CoV-2 variant's evolutionary trajectory

Researchers at the Division of Infection and Immunity, University College London, UK, have provided key insights into the characteristics of the B.1.1.7 (or UK) variant of SARS-CoV-2.

24 Mar 2021

Modeling study predicts SARS-CoV-2 variants with high receptor binding affinity

A new study adds to the sum of knowledge about SARS-CoV-2, with respect to its natural and biologically significant mutations, using computational modeling of the virus-receptor interactions. Understanding how viral mutations affect the virus-host interactions is crucial for shaping proper strategies to control the virus.

24 Mar 2021

Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function

A new study reports the essential nature of Fc-mediated functionalities in determining the efficacy of such antibodies.

24 Mar 2021

New covalent and non-covalent SARS-CoV-2 inhibitors discovered in silico

A new study describes the use of a combination of virtual and experimental screening protocols to identify potential inhibitors of the virus, which could lead to rapid drug development.

24 Mar 2021

Research suggests toothpaste and mouthwash ingredients could help prevent SARS-CoV-2 infection

Now, new research published on the bioRxiv preprint server focuses on the effect of some typical ingredients present in commercially available mouthwashes and toothpaste on the mechanisms of SARS-CoV-2 entry into host cells.

24 Mar 2021

Potent nanobody binds SARS-CoV-2 spike in an extraordinary manner

In a new study, published recently on the bioRxiv preprint server, researchers isolated a nanobody that potently neutralizes SARS-CoV-2, including the B.1.351 variant, and cross-neutralizes SARS-CoV. They demonstrated the therapeutic potential of the nanobody in a human ACE2 (angiotensin-converting enzyme) transgenic mouse model.

24 Mar 2021

Dandelion extract inhibits SARS-CoV-2 in vitro

An exciting new study describes a specific inhibitor of the SARS-CoV-2 found in an extract of the common dandelion that could provide a new and fruitful avenue of drug research.

23 Mar 2021

Ai helps identify critical interactions for SARS-CoV-2 spike protein binding to ACE2

Recently, researchers from the US employed multiple-µs molecular dynamic simulations to compare the relative dynamics, stabilities, and energy differences between the SARS-CoV receptor-binding domain (RBD)-ACE2 and SARS-CoV-2 RBD-ACE2 complexes. The study is published on the preprint server, bioRxiv.

23 Mar 2021

Angiotensin Converting Enzyme 2 News and Research

Development of a model of substrate coordination to Zn-bound ACE2

Researchers develop novel test that screens for SARS-CoV-2 variants of concern

Researchers develop broadly neutralizing SARS-CoV-2 ferritin nanoparticle vaccine

Using ACE2 structure to predict SARS-CoV-2 susceptibility in animals

Study identifies key features in SARS-CoV-2 genome essential for replication in respiratory cells

Addressing the increasing plasticity of SARS-CoV-2

Developing orally administrable drugs to combat SARS-CoV-2

Virus-cell interaction may partly explain the higher infection rate of COVID-19

Antibody agents effective at neutralizing European, South African, and United States SARS-CoV-2 variants

New SARS-CoV-2 genome variants identified in US mink

Identification of specific anti-SARS-CoV-2 antibodies with cross-neutralization potency

Fluoxetine (Prozac) performs strongly in vitro against SARS-CoV-2 (including mutants)

Pangolin coronavirus sheds light on UK SARS-CoV-2 variant's evolutionary trajectory

Modeling study predicts SARS-CoV-2 variants with high receptor binding affinity

Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function

New covalent and non-covalent SARS-CoV-2 inhibitors discovered in silico

Research suggests toothpaste and mouthwash ingredients could help prevent SARS-CoV-2 infection

Potent nanobody binds SARS-CoV-2 spike in an extraordinary manner

Dandelion extract inhibits SARS-CoV-2 in vitro

Ai helps identify critical interactions for SARS-CoV-2 spike protein binding to ACE2

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News